Clinical trial · Interventional
Implementing Precision Medicine in cOmmunity HospiTALs
NCT05283044CI-TRIAL-00091386PRISM-POrTALrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective biomarker study that aims at demonstrating the impact of liquid biopsy to deliver better treatment for cancer patients with metastatic disease managed in the community setting
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biopsy liquid | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Biopsy liquid contributive
- description
- Patients presenting for whom ct DNA sequencing
- interventionNames
- Biological: biopsy liquid
Primary outcomes (1)
- measure
- Proportion of patients for whom ctDNA sequencing
- timeFrame
- 72 months
- description
- The primary objective of the study will be to evaluate the impact of ctDNA sequencing on the treatment plan of cancer patients managed in satellite centers. This will be performed by estimating the proportion of patients for whom ctDNA sequencing has allowed to propose a systemic treatment that was not considered before the clinician.
Secondary outcomes (7)
- measure
- Utilization rates of molecular profiling information
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Participants are eligible to be included in the study only if they meet all of the following criteria: 1. Age ≥ 18 years 2. Histology: solid malignant tumor 3. Locally advanced/unresectable and/or metastatic (for prostate cancer: castration resistant prostate cancer, for RH+/HER2- breast cancer: prior treatment with endocrine therapy plus anti-CDK4/6 inhibitor) 4. Eastern Cooperative Oncology Group (ECOG) performance status \< 2 5. Measurable disease as per RECIST criteria 6. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code) 7. Voluntary signed and dated written informed consent prior to any study specific procedure. Exclusion Criteria: Participants will be excluded from the study if they meet any of the following criteria: 1. Radiological evidence of symptomatic or progressive brain metastases 2. Previous or current malignancies of others histologies within the last 2 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin and prostate cancer 3. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in a clinical trial or which would jeopardize compliance with the protocol 4. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent 5. Minors (Age \< 18 years) 6. Pregnant or breast-feeding women 7. Previous enrollment in the present study.
References
Publications (0)
Data not yet available
No reference posted for this study.